Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study.

Antifungal Agents / therapeutic use Candidiasis / drug therapy Caspofungin Echinocandins Humans Intensive Care Units Lipopeptides Microbial Sensitivity Tests Monte Carlo Method
PK/PD caspofungin intensive care unit invasive candidiasis pharmacokinetics

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
17 11 2020
Historique:
received: 18 07 2020
accepted: 13 09 2020
pubmed: 23 9 2020
medline: 22 6 2021
entrez: 22 9 2020
Statut: epublish

Résumé

This study evaluated the impact of a high loading dose of caspofungin (CAS) on the pharmacokinetics of CAS and the pharmacokinetic-pharmacodynamic (PK-PD) target attainment in patients in intensive care units (ICU). ICU patients requiring CAS treatment were prospectively included to receive a 140-mg loading dose of CAS. Plasma CAS concentrations (0, 2, 3, 5, 7, and 24 h postinfusion) were determined to develop a two-compartmental population PK model. A Monte Carlo simulation was performed and the probabilities of target attainment (PTAs) were computed using previously published MICs. PK-PD targets were ratios of area under the concentration-time curve from 0 to 24 h (AUC

Identifiants

DOI: 10.1128/AAC.01545-20 PMID: 32958709 PMC: PMC7674046
pubmed: 32958709
pii: AAC.01545-20
doi: 10.1128/AAC.01545-20
pmc: PMC7674046
pii:
doi:

Substances chimiques

Antifungal Agents 0
Echinocandins 0
Lipopeptides 0
Caspofungin F0XDI6ZL63

Banques de données

ClinicalTrials.gov
['NCT02413892']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

Infect Dis Ther. 2020 Mar;9(1):137-149
pubmed: 32026399
Int J Antimicrob Agents. 2018 Jan;51(1):115-121
pubmed: 28666752
Antimicrob Agents Chemother. 2002 Mar;46(3):739-45
pubmed: 11850256
Clin Infect Dis. 2005 Nov 1;41(9):1232-9
pubmed: 16206095
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30962329
Antimicrob Agents Chemother. 2013 Apr;57(4):1664-71
pubmed: 23335740
Antimicrob Agents Chemother. 2020 Oct 20;64(11):
pubmed: 32816724
Antimicrob Agents Chemother. 2011 Dec;55(12):5798-803
pubmed: 21911573
J Infect. 2016 Jan;72(1):103-11
pubmed: 26518058
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37
pubmed: 23137135
Virulence. 2014 Jan 1;5(1):161-9
pubmed: 24157707
Antimicrob Agents Chemother. 2010 Jun;54(6):2497-506
pubmed: 20385855
Clin Infect Dis. 2013 Jun;56(12):1724-32
pubmed: 23487382
J Antimicrob Chemother. 2007 Jul;60(1):100-6
pubmed: 17525052
J Antimicrob Chemother. 2011 Dec;66(12):2880-6
pubmed: 21980066
Int J Antimicrob Agents. 2016 May;47(5):397-402
pubmed: 27068676
Clin Infect Dis. 2006 Jul 1;43(1):25-31
pubmed: 16758414
Clin Infect Dis. 2016 Feb 15;62(4):409-17
pubmed: 26810419
Diagn Microbiol Infect Dis. 2014 Aug;79(4):441-7
pubmed: 24985764
Intensive Care Med. 2014 Jun;40(6):839-45
pubmed: 24807083
Antimicrob Agents Chemother. 2011 Feb;55(2):532-8
pubmed: 21078946
Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38
pubmed: 29544767
Clin Infect Dis. 2014 Sep 15;59(6):819-25
pubmed: 24879785
Intensive Care Med. 2013 Dec;39(12):2070-82
pubmed: 24045886
Ann Intensive Care. 2016 Dec;6(1):2
pubmed: 26743881
Clin Infect Dis. 2009 Jun 15;48(12):1676-84
pubmed: 19419331
Crit Care Med. 2018 Mar;46(3):384-393
pubmed: 29189345
Clin Infect Dis. 2007 Jan 1;44(1):79-86
pubmed: 17143821
Emerg Infect Dis. 2012 Jan;18(1):86-90
pubmed: 22257484
Antimicrob Agents Chemother. 2005 Dec;49(12):5058-68
pubmed: 16304173
Crit Care. 2015 Feb 04;19:33
pubmed: 25888060
Clin Pharmacokinet. 2017 Sep;56(9):1057-1068
pubmed: 28035589
Crit Care Med. 2006 Mar;34(3):730-7
pubmed: 16505659
Antimicrob Agents Chemother. 2003 Apr;47(4):1179-86
pubmed: 12654644
Intensive Care Med. 2019 Jun;45(6):789-805
pubmed: 30911804
J Chemother. 2017 Dec;29(6):376-379
pubmed: 28198656
Clin Infect Dis. 2012 Jun;54(12):1739-46
pubmed: 22423135
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27855112
Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5
pubmed: 16127033
Intensive Care Med. 2014 Sep;40(9):1303-12
pubmed: 25097069
Antimicrob Agents Chemother. 2010 May;54(5):1815-9
pubmed: 20176892
Crit Care. 2016 May 27;20(1):125
pubmed: 27230564
Clin Infect Dis. 2009 Jun 15;48(12):1695-703
pubmed: 19441981
Bone Marrow Transplant. 2007 Feb;39(3):157-64
pubmed: 17245424
J Antimicrob Chemother. 2014 Dec;69(12):3294-9
pubmed: 25139840
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Emerg Infect Dis. 2014 Jul;20(7):1149-55
pubmed: 24960557

Auteurs

Sébastien Bailly (S)

Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.
ORCID: 0000-0002-2179-4650

Elodie Gautier-Veyret (E)

Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.
Laboratory of Pharmacology-Pharmacogenetics-Toxicology, Biology and Pathology Department, CHU Grenoble Alpes, Grenoble, France.
ORCID: 0000-0002-5846-3847

Minh P Lê (MP)

AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, UMR 1137, IAME, INSERM/Paris Diderot University, Paris, France.
INSERM UMR_S 1144, Université de Paris, Paris, France.
ORCID: 0000-0002-4670-8288

Lila Bouadma (L)

Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.
UMR 1137, IAME, INSERM/Paris Diderot University, Paris, France.

Olivier Andremont (O)

Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.

Mathilde Neuville (M)

Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.
UMR 1137, IAME, INSERM/Paris Diderot University, Paris, France.

Bruno Mourvillier (B)

AP-HP, Medical and Infectious Diseases ICU (MI2), Bichat-Claude Bernard University Hospital, Paris, France.
UMRS 1136, iPLESP, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Sorbonne Université, Paris, France.

Romain Sonneville (R)

Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.
UMR 1137, IAME, INSERM/Paris Diderot University, Paris, France.
AP-HP, Medical and Infectious Diseases ICU (MI2), Bichat-Claude Bernard University Hospital, Paris, France.
UMRS 1136, iPLESP, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Sorbonne Université, Paris, France.
UMR 1148, Laboratory for Vascular and Translational Science, INSERM/Paris Diderot University, Paris, France.

Eric Magalhaes (E)

Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.

Jordane Lebut (J)

Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.

Aguila Radjou (A)

Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.

Roland Smonig (R)

Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.

Michel Wolff (M)

Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.
UMR 1137, IAME, INSERM/Paris Diderot University, Paris, France.

Laurent Massias (L)

AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, UMR 1137, IAME, INSERM/Paris Diderot University, Paris, France.
INSERM UMR_S 1144, Université de Paris, Paris, France.
Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.
UMR 1137, IAME, INSERM/Paris Diderot University, Paris, France.

Claire Dupuis (C)

Medical ICU, Gabriel-Montpied University Hospital, Clermont-Ferrand, France.

Jean-François Timsit (JF)

Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France jean-francois.timsit@aphp.fr.
UMR 1137, IAME, INSERM/Paris Diderot University, Paris, France.
ORCID: 0000-0002-6063-7383

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antifongiques › Impact of Loading Dose of Caspofungin in...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Mycoses › Candidose › Impact of Loading Dose of Caspofungin in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Peptides cycliques › Échinocandines › Caspofungine › Impact of Loading Dose of Caspofungin in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Peptides cycliques › Échinocandines › Impact of Loading Dose of Caspofungin in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Impact of Loading Dose of Caspofungin in...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Établissements de santé › Unités hospitalières › Unités de soins intensifs › Impact of Loading Dose of Caspofungin in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Lipopeptides › Impact of Loading Dose of Caspofungin in...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Impact of Loading Dose of Caspofungin in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Méthode de Monte Carlo › Impact of Loading Dose of Caspofungin in...